|
Mirvetuximab Soravtansine Clinical Trials
3 actively recruiting trials across 3 locations
▼ -1 trial since August 2026
Also known as: ELAHERE™, IMGN853, MIRV
Pipeline
Phase 2: 3
Top Sponsors
- AbbVie3
Indications
- Cancer3
- Primary Peritoneal Cancer2
- Advanced High-Grade Epithelial Ovarian Cancer1
- Platinum Resistant1
- High Folate Receptor-Alpha Expression1
Birmingham, Alabama1 trial
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
University of Alabama at Birmingham (UAB) Hospital /ID# 274793
Phase 2
La Jolla, California1 trial
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
UC San Diego Health - Moores Cancer Center /ID# 277574
Phase 2
Sarasota, Florida1 trial
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
First Physicians Group /ID# 272180
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.